Analysts think ANAB stock price could increase by 55%
Jul 10, 2025, 11:25 AM
-4.04%
What does ANAB do
AnaptysBio, a clinical-stage biotechnology company based in San Diego, focuses on immune cell modulators and has two checkpoint agonists in Phase 2 trials for autoimmune diseases. The company went public on January 26, 2017, and employs 117 staff.
13 analysts think ANAB stock price will increase by 54.61%. The current median analyst target is $39.78 compared to a current stock price of $25.73. The lowest analysts target is $18.18 and the highest analyst target is $94.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
